SESSION TITLE: COPD Pharmacotherapy
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM
PURPOSE: Glycopyrronium (GLY) is a once daily (od) long-acting muscarinic antagonist (LAMA) for maintenance treatment for patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). The GLOW7 study studied the efficacy and safety of GLY 50µg od in Asian (predominantly Chinese) patients. We report here a comparison of the efficacy and safety of GLY in the Chinese cohort in the GLOW7 study vs results in predominantly Caucasian populations (GLOW1 and GLOW2 studies) with similar severity of COPD.